Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 4, 2025
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether taking aspirin and folic acid can help people who suddenly lose hearing in one ear, a condition called sudden sensorineural hearing loss (SSNHL). Researchers think that problems with tiny blood vessels in the inner ear might cause this sudden hearing loss. They want to see if these medicines can improve blood flow and protect the ear from damage.
The study is looking for adults who have experienced a sudden drop in hearing in one ear—specifically, a loss of at least 30 decibels in three connected sound frequencies—within the past 15 days. Participants must be able to follow the study rules and be part of a social security system. People who have certain health conditions, allergies, or take specific medicines like aspirin or antidepressants that affect serotonin will not be able to join. If you take part, you’ll be monitored to see how well the treatment works and if it is safe. This study has not started recruiting yet, but it aims to find better ways to treat sudden hearing loss and help patients recover their hearing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral SSNHL defined as a sudden hearing loss of 30dB or greater at least three contiguous audiometric frequencies (between 125hz and 8000Hz) occurring within a 72 hr period and for less than 15 days.
- • Individuals affiliated to a social security regimen
- • Individuals able to participate and to follow up during the study period
- Exclusion Criteria:
- • Contra-indications to Aspirin, contra-indications to oral corticosteroid therapy, contra-indications to dexamethasone, allergy to vitamin B9
- • Evident cause of acute SSNHL including tumor of the ponto-cerebellous angle, infectious labyrinthitis, mechanical and acoustic trauma, malformation of the inner ear, neurological disorder.
- • Patient already including in another clinical trial
- • Person under legal protection (under guardianship or curatorship)
- • Patients taking serotonin reuptake inhibitors
- • Patients already taking aspirin or other anticoagulant or antiplatelet agent
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Ile De France, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported